A brief overview of pituitary adenomas, their subtypes, classification, investigation protocols, radiological evaluation, and their medical management.
Call Girls Nagpur Just Call 9907093804 Top Class Call Girl Service Available
Pituitary adenomas: Clinical, neuro-ophthalmic, radiological evaluation and medical management
1. PITUITARY ADENOMAS
Presenter: Dr Kaushal Deep Singh
Moderator: Dr Abrar Ahad Wani
Sher-i-Kashmir Institute of Medical Sciences
(SKIMS), Soura, Srinagar
Date: 08/05/2019
3. Did you know??
• Robert Wadlow was
the tallest recorded
man on earth at a
height of 8 ft 11 in.
• His astounding
height was the
result of a pituitary
tumor.
5. PITUITARY GLAND – AN
OVERVIEW
Weighs just 600 mg
Cranio-caudal dimensions 8-10mm
Exercises direct or indirect control on every organ
system
Sella turcica - part of body of sphenoid bone
Depth- upper limit 13mm
Length - upper limit 17mm
Width - upper limit 15 mm
Volume - 1100 mm3
6.
7.
8.
9.
10.
11. Adenohypophysis
Secretes GH, PRL, FSH, LH, TSH, ACTH, MSH,
Endorphins.
Adenohypophysis : divided into Pars tuberalis, Pars
intermedia, Pars distalis
Delicate acinar architecture
In horizontal cross section, composed of two lateral
wings and trapezoid central mucoid wedge
PITUITARY GLAND – AN
OVERVIEW
12.
13. Somatotrophs Anterior part of the lateral wings
Lactotrophs Posterior part of the lateral wings
Corticotrophs Central wedge , just anterior to
posterior lobe
Thyrotrophs Anteromedial part of central
wedge
Gonadotrophs Through out pars distalis
PITUITARY GLAND – AN
OVERVIEW
14. Neurohypophysis
• Contains only axons and fenestrated
capillaries
• Divided into
median eminence
infundibular stem
neural lobe
PITUITARY GLAND – AN
OVERVIEW
15.
16. Cell type hormone Clinical syndrome Tumor type
Somatotroph Growth
Hormone
Acromeg/gigan Sparsely granulated GH cell
Densely granulated GH cell
Lactotroph Prolactin Amen/galactor Sparsely granulated prl
Densely granulated prl
Somato/Lact Gh+prl Acro+hyperprl Mixed GH-prl
Acro+hyperprl Mammo+somato
Amen/Gal/Acro Acido+stem cell
Corticotroph Acth/Pomc
/B-lph/Msh
Cushings, nelson Densely granulated acth
Sparsely granulated acth
Gonadotroph FSH,LH,A-
Sub Unit
Hypopituitarism Gonadotroph
Thyrotroph TSH, A-sub
Unit
Hyperthyroid/
Hypopituitarism
Thyrotroph
NULL Cell None Hypopituitarism Null cell
oncocytoma
18. PITUITARY TUMOURS
10-15% of all primary
brain tumours; Present
as incidental finding in
5-20%
Annual incidence of 8.2
– 14.7 case / 100000
population
Though incidence is
equal, it is diagnosed
more commonly in
females
19. Third most
common primary
brain tumours
Autopsy
incidence: 20-
25% of
population
10% of routine
MRI scans show
occult pituitary
microadenoma
Between 3rd – 6th
decade of life
20. PITUITARY TUMOURS
Genetics
MEN 1
3% of all pituitary tumours
Autosomal dominant disorder
Variable penetrance
Occurs in 25% of affected patients with MEN 1
PRL or GH macroadenomas
27. Hypersecretion
70% of pituitary adenomas
are endocrinologically active
Most common mode of
presentation
Presentation varies according
to the hormone in excess
28. Pituitary Insufficiency
By compression of
non-tumourous
pituitary, pituitary
stalk, hypothalamus
Chronic process,
can be acute as in
pituitary apoplexy
Gonadotrophs most
vulnerable
30. Non-functioning Adenomas
25-30 % of patients do not have classical
hypersecretory syndromes
May grow to a large size before they are
detected
Present due to mass effect
Visual deficits
HA
Hormone deficiency
31. • Acute presentation secondary to tumor
hemorrhagic necrosis/infarction
• Headache
• Vomiting
• Blindness
• Ocular paresis
• Altered level of consciousness
• Occur in pregnancy
• Compresses hypophysial portal vessels
• Treatment : high dose steroid / early surgery
Apoplexy
32. Clinical Manifestations
Hormonal deficiencies - Clinical effects
Growth hormone
deficiency
• Adults - Increased rate
of cardiovascular
disease, obesity,
reduced muscle strength
and exercise capacity,
and increased
cholesterol
• Infants –Hypoglycemia
• Children - Decreased
height and growth rate
Gonadotrophin deficiency
• Men - Diminished libido and
impotence; testes shrink in
size, but spermatogenesis
generally preserved
• Women - Diminished libido
and dyspareunia; breast
atrophy in chronic deficiency
• Children - Delayed or frank
absence of puberty
Thyrotropi
n
deficiency
• Malaise,
• weight gain,
• lack of energy,
• cold intolerance,
• constipation
33. Clinical Manifestations
Hormonal deficiencies - Clinical effects
Corticotrophin deficiency
• Initially, symptoms nonspecific (eg, weight
loss, lack of energy, malaise); severe adrenal
insufficiency may present as a medical
emergency
Panhypopituitarism
Refers to
deficiency of
several anterior
pituitary
hormones.
34. Clinical Manifestations
Hormonal overproduction - Clinical effects
Prolactin *
• Hypogonadism, if
hyperprolactinemia
sustained
• Women -
Amenorrhea,
galactorrhea, and
infertility
• Men - Decreased
libido, impotence,
and rarely
galactorrhea
Growth hormone
• Children and adolescents - May result
in pituitary gigantism
• Adults – Acromegaly Changes in the size
of the hand and feet, coarseness of the
face, frontal bossing, and prognathism
result. Further changes in the voice, and
hirsutism, confirm the diagnosis.
• Acromegaly frequently results in
glucose intolerance, with 20% of
patients progressing to diabetes
mellitus.
• Carpal tunnel syndrome is seen
frequently.
Cushing
disease
• Weight gain,
central
obesity,
moon facies,
violet striae,
easy
bruisability.
37. HARDY’S Classification
Microadenomas – Grades 0 and I
Macroadenomas – Grades II to IV
Grade 0 : Intrapituitary microadenoma with
normal sellar floor, size < 10 mm
Grade I : Normal-sized sella with asymmetric floor, size <
10 mm
Grade II : Enlarged sella with an intact floor, size > 10
mm
Grade III : Localized erosion of sellar floor, size > 10 mm
Grade IV : Diffuse destruction of floor, size > 10 mm
38. Modified Hardy Wilson Classification
Type A: Tumor bulges into the
chiasmatic cistern
Type B: Tumor reaches the
floor of the 3rd ventricle
Type C: Tumor is more
voluminous with extension
into the 3rd ventricle up to the
foramen of Monro
Type D: Tumor extends into
temporal or frontal fossa
TYPE E : Extradural spread
(extension into or out of the
cavenous sinus)
40. WHO Classification
Five-tiered
system
• Clinical presentation and
secretory activity
• Size and invasiveness (e.g.
Hardy)
• Histology (typical vs. atypical)
• Immunohistologic profile
• Ultrasturctural subtype
41. Microadenoma < 10 mm diameter Secreting adenoma
Macroadenoma > 10 mm diameter Mass effects
Non secreting
Classifying Adenomas by Size
42. Classification Of Pituitary Adenomas According
To Endocrine Function
Pituitary adenomas are classified by their cell of
origin
Lactotroph adenoma
Gonadotroph adenomas
Somatotroph adenomas
Corticotroph adenomas
Thyrotroph adenomas
43.
44.
45. Classification Of Pituitary Adenomas According
To Cells of Origin
Adenomas With
GH excess
PRL excess
ACTH excess
TSH excess
FSH / LH excess
PLEURI hormonal adenomas
Adenomas With No Apparent Hormonal Function
47. Prolactin
< 25 ng/ ml : normal
25-150 ng/ml:
prolactinoma
stalk effect
drugs
Hypothyroid
> 150 ng/ml : prolactinoma
Hook effect
even large elevations will show normal PRL levels on
testing due to large size of molecules. Do serial
dilutions
48. A. Prolactinomas
Most common primary tumour of pituitary
30% of all pituitary adenoma
Female:male = 20:1 for microadenoma
1:1 for macroadenoma
Characterized by hyperprolactinemia
Majority are microadenomas; 30% in females are self-limiting
Prolactin
< 25 ng/ ml - normal
25- 150 ng/ml - prolactinoma(±), stalk effect, drugs,
hypothyroidism
> 150 ng/ml - prolactinoma (pure or mixed)
> 1000 ng/ml - invasive prolactinomas
52. Prolactin Function
Serum prolactin levels ( normal 5-20ng / ml)
Dynamic tests:
not used if prolactin levels > 150ng / ml or tumor is found on
MRI / CT
used if prolactin levels are mildly elevated and MRI findings are
equivocal
Stimulation tests :
TRH
Chlorpromazine
Metoclopramide
Suppression tests:
L-dopa
Nomifensine
53. Prolactinomas
Only pituitary tumor for which medical
therapy has a proven primary role
Observation
Dopamine agonist
Bromocriptine
Cabergoline
54. Dopamine agonist
Selective activation of D2 receptors located on
lactotroph cell surface
↓
Decrease adenylate cyclase activity
↓
Decrease in C- AMP level
↓
Inhibition of PRL synthesis and release.
56. Prolactinomas
Indications for dopamine agonist therapy:
Non invasive prolactinoma and serum prolactin
level 150-500ng/ml
Serum prolactin level >1000ng/ml
Residual / recurrent prolactinoma following
surgery
58. Serum levels peak after 3 h, and the nadir is observed at
7 h with very little bromocriptine detectable in the
circulation after 11-14 h.
Absorption rate from the GI tract is 25-30%.
Very high first-pass effect, with 93.6% of a dose being
metabolized and only 6.5% of an absorbed dose
reaching the systemic circulation unchanged
Excreted via the biliary route into the feces
Levels in the fetus about one-fourth of that found in
maternal blood
Start low dose at 1.25 - 2.5 mg day at night before
increasing to 2.5 – 10 mg per day in divided doses
Take with food to reduce side effects
59. Cabergoline:
more effective
less side effects than Bromocriptine
more expensive
given once or twice a week with a starting dose of
0.25 mg 2 x week
Titrate these based on prolactin levels and tolerability
60. Criteria for cure:
Normal prolactin level
Asymptomatic
Negative MRI study for 5 years
If prolactin level is <100ng/ml and shows no
tendency to rise is indicative of stalk damage
61. B. Growth Hormone Secreting
Pituitary Adenomas
Growth hormone
• Most abundant pituitary hormone
• Secretion is pulsatile
• Physiological excess seen in stress, trauma,
sepsis, estrogen replacement
• Exerts it’s action through IGF -1
62. Growth Hormone Secreting Pituitary
Adenomas
Equal incidence in males and females
More than 60% are macroadenomas
4th and 5th decade
15-20% of all pituitary tumors
Pre-op duration 10 years to diagnosis in adults and 3.1 years in
children
Pleurihormonal
Overall mortality is increased 3 folds as compared to age matched
controls
64. Diverse Manisfestations
1. BONE AND
SOFT TISSUE-
coarse facial
features
frontal bossing,
prognathism,
maxillary
widening,
dental
malocclusion
Snoring sleep
apnea, low voice
Macroglossia
Spade like
enlargement of
hand and feet
Malodorous/oily
perspiration
2. CARDIOVASCULAR
HYPERTENSION
CARDIOMYOPATHY
ARRHYTHMIAS
3.Musculoskeletal
Arthropathies
Kyphosis
Spinal stenosis
Barrel chest
Osteoarthritis
4. Increased incidence of premalignant
polyps/ colonic cancers
5.Diabetes mellitus
65.
66. Acromegaly work-up
Chest and abdomen imaging for ectopic GHRH
secreting tumors
Empty sella shows pituitary infarction
Scintigraphy
Ancillary tests
Blood glucose, urine, cardiac and respiratory
screening for colorectal neoplasia
67. Diagnosis
Random GH – not useful gives false positive and false
negative results
Insulin like growth factor 1 (IGF-1) – best
for screening (represents average daily GH secretion)
Insufficient GH suppression on oral
glucose tolerance testing – gold standard to
confirm diagnosis : 75 mg of glucose load normally suppresses
GH< 2ng/ml RIA. GH nadir >2ng/ml RIA with adenoma confirms it
68. Somatomedin-C (IGF-1) : always elevated in acromegaly
GH levels: fasting state and after administration of
stimulatory or inhibitory agents
Stimulatory tests :
Insulin induced hypoglycemia after IV administration of 0.1-
0.15 IU/Kg of plain insulin
GH level >5ng / ml indicates normal function
it is avoided in elderly, those with cerebro vascular disorders
or convulsive disorder
Oral glucose suppression test: Failure of suppression of
elevated levels of GH to < 2ng / ml after 75 gm glucose
loading
Acromegaly
69. Clinically Acromegaly, MRI pit adenoma, GH>5ng/ml
If GH<5ng/ml
IGF-1, elevated
If no
Oral glucose suppression test confirms it
rarely MRI negative ,
measure GHRH levels, CECT abd /chest
70. Acromegaly
Indications of medical management:
Failure of surgery to normalize IGF 1 levels
Awaiting the beneficial effects of RT
Unresectable tumors
73. Somatostatin analogues:
Octreotide :45 times more potent.
half-life in plasma being 113 min
peak plasma concentrations within 1 h
suppress GH levels for 6–12 h
Mechanism of action
Inhibit GH secretion
partially inhibits GH-induced IGF-1 generation
simulates IGF-BP1 expression
reduce GHRH release
74. Clinical improvement-
headache 84%
hyperhydrosis 65%
decrease in ring size in 55%
improvement in cardiac function and sleep
apnea
75. Octreotide
(S/C) 100 to
500 mic.gm
TDS
Octreotide
LAR
(I/M) at 28
days interval
Lanreotide
(I/M) every 7-
14 days
Pegvisomant
GH
REDUCTION
47% 56% 50% Not useful
IGF1
REDUCTION
46% 66% 48% 97%
76. Dopamine agonists :
Used both as primary and adjuvant
treatment
Bromocriptine up to 20 mg/day
Cabergoline 1–2 mg/week
Response rate low
79. C. ACTH Secreting Pituitary
Adenomas (Cushing’s Disease)
• 5 to 10 times more common in females than
males
• 3rd and 4th decade
• 10-15% of all pituitary tumors
• 90% microadenomas
• 55 % pit adenoma in children
• Highest morbidity of all pituitary hypersecretory
disorders
• Most common cause of death is cardiovascular
complication
80. Cushing’s Disease
Chronic Exposure of Tissues to Excessive Cortisol
Moon facies
Centripetal obesity
Buffalo hump
Thin skin ,purple abdominal striae, ecchymosis
Psychological
Glucose intolerance
Hematopoietic features include leukocytosis, lymphopenia, eosinopenia
Osteoporosis, proximal myopathy,
Impaired immune function
Hirsutism, acne menstrual irregularities in females
Oligospermia, impotence in males
81.
82. Cushing’s Syndrome vs. Cushing’s
Disease
Cushing’s syndrome is a syndrome due to
excess cortisol from pituitary, adrenal or other
sources (exogenous glucocorticoids, ectopic
ACTH, etc.)
Cushing’s disease is hypercortisolism due to
excess pituitary secretion of ACTH (about 70%
of cases of endogenous Cushing’s syndrome)
83. Evaluation Of Suspected Cushing`s
Syndrome
HISTORY: increased weight, growth retardation
in children , weakness, easy bruising, stretch
marks, poor wound healing, fractures, change in
libido, impotence, irregular menses, mood
changes
EXAMINATION – fat distribution, hypertension,
proximal muscle weakness, thin skin and
ecchymoses, purple striae, hirsutism, acne, facial
plethora, edema.
84. Corticotroph adenomas
Laboratory Evaluation
1. Establishing hypercortisolism
2. Distinguishing ACTH- dependent from ACTH
independent causes of hypercortisolism
3. Differentiating Cushing’s disease from
ectopic states of ACTH excess
85. Establishing hypercortisolism
Urinary free cortisol
Sensitivity 45–71%,100% specificity (best screening test)
Overnight dexamethasone suppression test or Low dose
dexamethasone suppression test (Liddle test)
Sensitivity 95 % and specificity 88%
1 mg of dexa at 11.00 am and measurement of serum cortisol
at 8.00 am
<5 mcg/dl- normal
5-10 mcg/dl equivocal
>10mcg diagnostic
Plasma corticotropin level->20pg/ml diagnostic
>10 pg/ml suggestive
<5pg/ml corticotroph independent
86. Nocturnal Salivary Cortisol:
93% sensitivity, 100% specificity.
Levels < 4.0 nmol/l, the diagnosis of
significant Cushing’s syndrome is unlikely
7–8 nmol/l are abnormal
87. Establishing ACTH Dependency
Measurement of plasma ACTH levels
ACTH level <1.1 pmol/L (5 pg/mL) by IRMA is
consistent with an ACTH-independence
Corticortroph adenoma: moderate elevation
Ectopic ACTH producing lesion: marked
elevation
88. Differentiating Cushing’s disease
from ectopic states of ACTH excess
High dose dexamethasone suppression test (if
corticotrops >10 pg/ml): 2 mg qid for 48 hrs and
measurement of urinary cortisol/17-
hydroxycorticosteroid; > 69% fall in 24 hr UFC (pre
and post dexa ) is 100% specific for CD
Overnight 8 mg dexamethasone test: 8 mg
dexamethasone is given at 11.00 pm and drop in
>50% S. cortisol at 8 AM indicates CD.
CRH stimulation test: 1 mcg/kg CRH IV in morning, if
increases >35% corticotropin level at 15, 30 min
above baseline yields 100% specificity and 93%
sensitivity for CD
Metyrapone Test (inhibitor of 11β-hydroxylase)
89. Inferior petrosal sinus
sampling
Classical clinical and biochemical CD features with
MRI negative patient equivocal suppression and
stimulation test
Diagnostic accuracy is 80-100%
Blood samples are obtained at basal and 3,5,10 min
after CRH administration and ips/ps ratio calculated
ips/ps >3 CD
ips/ps <2 ectopic
rarely 2-3 ectopic
IPS gradient helps in lateralization of adenoma
95. Cushings disease
Indications for medical management:
Failure of all other treatment modalities
Preparation for surgery to relieve extreme
symptoms
Interval between RT and development of
eucortisolemia
97. Ketoconazole: First line drug
17α-hydroxylase,11β-hydroxylase,18-
hydroxylase, and especially 17,20-lyase
enzymes are all blocked by ketoconazole
400–1200 mg/d (average 800 mg/d)
Effective in 70-100%
Liver toxicity 15%
98. Aminoglutethimide
Inhibits the first step in cortisol biosynthesis
(cholesterol → pregnenolone)
Effective 50%
250-2000 mg/day
Can be given with ketoconazole
100. Mitotane
Adrenocorticolytic effects and direct inhibition of
steroid synthesis
2-4 g/day
Effective in 80%, long term remission in 30%
Higher response rate with concomitant pituitary
irradiation
Contraindicated in women planning for pregnancy
within 5 years
Side effects : gastrointestinal, hypercholesterolemia,
adrenal insufficiency
101. Etomidate
Life-threatening situations with severe
hypercortisolism
Oral dosing is contraindicated
Dose of 0.1 mg/kg/h
Eucortisolism achieved within 11–48 h by
using a continuous infusion
105. D. Thyrotroph adenoma
TSH secreting tumors
1-2% of pit adenomas
Mixed hormonal secretion- 30%
GH, PRL, Gonadotropins
90% macroadenomas
Mean duration of presentation 9 yrs
Clinical features of goitre, warm skin, heat
intolerance, cardiac arrhythmias and other
hyperthyroid features,
106. Thyrotropic Function
T3 , T4 , TSH levels, Free T4, T3 by direct method, a-
subunit, PRL, GH, SHB, Iodine scan/USG of thyroid
If TSH levels are normal in the presence of low T3 / T4
levels then TRH reserve is tested
200 micro grams of TRH is given IV – if TSH is elevated
to > 6-20 micro units / ml : normal
absence of response :
total hypophysectomy
Decreased response:
thyroid hormone therapy
glucocorticoid therapy
Hyperthyroidism
renal failure
depression
107. Clinical suspicion, MRI –pit adenoma, baseline TSH,
free T4/T3,a-sub unit,PRL,GH
TSH normal, a-sub unit/TSH ratio
<5.7 in normogonads,<29.1 in hypergonad,
TSH elevated<0.7 in normogonads,
<1.0 in hypergonads
MRI equivocal, TRH stimulation test
109. E. Gonadotropinomas
7-15% of pituitary adenomas
40-50% macroadenomas secrete
gonadotropins
Clinical features of mass effect: visual
symptoms, hypogonadism, amennorrhea,
hypothyroid, hypocortisolism
110. Gonadotropinomas
Lab investigations
• basal hormonal levels
• TRH stimulated gonadotropins, and sub
units
normally causes absent FSH response and no more
than 33% increase in LH and b- LH
primary hypogonadism LH,FSH elevated and don’t
respond to TRH
gonadotropinomas have greater than 60% increase
in b-LH levels
111. E. Gondotroph Function
CRITERIA :
Absence of other hormonal abnormality
Elevated basal and stimulated response of
gonadotropins
112. E. Diabetes Insipidus
Polyuria secondary to water diuresis and polydipsia
Due to low levels of ADH
High output of dilute urine
Craving for water, especially ice cold water
Incidence
9.2% in micro adenoma surgery
37% in case of total hypophysectomy
Mostly due to extreme sensitivity of hypothalamic
neurohypophyseal unit to local alterations in blood flow,
edema and traction on pituitary stalk and is transient
Permanent disturbance of ADH secretion –direct damage to
neuro hypophyseal unit
113. Types of presentation
Transient polyuria starting 1‐3 days after surgery and
lasting for 1‐7 days ; local edema and traction on
pituitary stalk
Triphasic response
polyuria beginning 1‐2 days after surgery lasting for 4‐5 days
normalization of urine output / SIADH like water retention 4‐5
days
return of polyuria
Transient polyuria begining immediate post-op
Permanent polyuria beginning immediate post-op and
continuing without any interphase
114. DIAGNOSIS:
Urine output >250ml/hr (>3ml/kg/hr in pediatric
patients )
Urinary S.G. < 1004
Urinary osmolality <200mosm/kg
Normal or above normal serum sodium level
Normal adrenal function
115. Depends on :
Patients clinical status
Urine volume
Concentration of serum electrolytes
Creatinine
If alert, with intact thirst, mild DI,
Patient can self regulate water intake
DDAVP – nasal spray 2.5micro gm BD
If thirst mechanism is impaired
‐meticulous I/o records
‐daily wt measurement
‐frequent electrolytes , urea , hematocrit
‐supplementation of free water
‐vasopressin analogues
116. If consciousness is impaired
Hourly I/O, urinary specific gravity
4 hourly electrolytes
Parenteral fluids
Titrated dosages of desmopressin‐2‐4
microgm IV/SC in 2 divided doses
117. Chronic DI
• Rare in c/o trans sphenoidal surgery
• Treatment of choice is DDAVP
• Other drugs :
clofibrate 500mg 2‐4 times/d
chlorpropamide –50‐500 mg/day
carbamazepine 400‐600mg/day
118. SIADH
Less common
Causes :
Pre-op medications
Anaesthetic agents
Surgical stress
Surgical irritation of neurohypophyseal unit
126. Neurophthalmics of Pituitary
Adenoma
OPTIC NERVE consists of 1.5 million fibres.
Total length is 5 cm of which 12-16 mm is
intracranial
Both optic nerves after coming out of optic canal
rise by 45 degrees and meet to form optic chiasm
127. Neurophthalmics of Pituitary
Adenoma
Optic Chiasm can be
Prefixed 15%
Normal 70%
Post fixed 15%
With in the chiasm
• PMB lies in the middle
• Temporal hemi retinal fibers pass
ipsilateraly
• Nasal hemi retinal fibers decussate
128. Neurophthalmics of Pituitary
Adenoma
Optic chiasm decussation
Inferior nasal fibers - anteroinferior
Superior nasal fibers - posterosuperior
PMB - in the middle primarily
posterosuperiorly
129. Neurophthalmics of Pituitary
Adenoma
Enlarging pituitary adenoma may compress
Optic chiasm
Optic nerve in patients with postfixed chiasm
Optic tracts in patients with prefixed chiasm
3rd , 4th, 6th nerves with cavernous sinus extension
causing diplopia
Diplopia evaluation: 3 principles
• abnormal image is always peripheral
• is always from the paretic eye
• distance between the image increases on looking in the
direction of paretic muscle
Third ventricle compression leading to hydrocephalus
132. Neurophthalmics of Pituitary
Adenoma
Visual evaluation in a case of pituitary
adenoma includes examination of:
Visual acuity
Colour vision
Visual fields
Opthalmoscopy
Pupils
Extraocular movements
133. Neurophthalmics of Pituitary
Adenoma
VISUAL ACUITY
Eye’s ability to resolve details
Neurosurgically, patient’s best corrected visual acuity
is pertinent
Distant vision by Snellen’s chart placed at 6 metres
where accommodation is relaxed and light rays are
parallel
Near vision by Rosenbaum’s pocket chart held at a
distance of 14 inches
134. Neurophthalmics of Pituitary
Adenoma
COLOUR VISION
• Loss of color vision precedes other visual
deficits
• In neurosurgical disease, red perception is
lost first described as red desaturation or red
wash outs
• Ishihara/hardy Ritter rand charts are used
135. Neurophthalmics of Pituitary
Adenoma
Visual Fields
90 -100 deg temporally
60 deg nasally
50-60 deg superiorly
60-75 deg inferiorly
• With binocular vision, VF of both eyes overlap
• Visual fields are analyzed by
Confrontation method
Goldman’s perimeter
Humphrey’s field analyzer
136.
137. Bitemporal hemianopia
Incongruous homonymous hemianopia
Bitemporal central scotoma
Diffuse scotoma
Junctional scotoma
Visual Field Defects in Pituitary
Macroadenoma
138. Classic defect in
pituitary adenoma
Occurs in central
chiasmal defect
Superotemporal field
affected first
↓
Lower temporal
field defect
Bitemporal Heminopia
139. Occurs in optic tract
lesion
Occurs in post.
Chiasmal lesion
Compressing only the
macular fibers
Bitemporal central
scotoma
Incongruous
Homonymous
heminopia
140. Central scotoma in one
eye with superotemporal
visual field loss in the
other eye
Caused by compression
to anterior loop to the
decussating nasal fibers
in posterior optic nerve
(Von Wilbrand's knee)
Junctional Scotoma
141. Vessels emerge from nasal side of disc. Arteries are narrower than veins.
Optic disc appears pink with sharp margins and a cup-to-disc ratio of approximately
0.35. The vasculature is normal in course and caliber.
142. Neurophthalmics of Pituitary Adenoma
• Pituitary adenoma can cause primary optic
atrophy.
Primary Secondary
Colour of disc white grey
Border of disc Sharp Blurred
Arteries and veins Normal or reduced Arteries thin, veins
dilated
Distribution May affect one sector Entire disc affected
Causes Optic nerve/retinal
damage
Papillitis/papilledema
Lamina cribrosa visible Not visible
145. Visual Evoked Potentials
Evoked electro physiological potential that
can be extracted using signal averages from
EEG activity recorded at the scalp.
Provides diagnostic information regarding the
functional integrity of visual system.
Measures the time taken for visual stimuli to
travel from eye to occipital cortex.
Particularly useful in infants
147. X-Rays
• Requires proper alignment of posterior
clinoid processes
widening of sella
destruction of sellar floor
relation of median sphenoidal septum
aeration of sphenoid sinus – conchal,
sclerotic, mixed
148.
149. CT Head
CT HEAD is especially useful for:
Evaluating bony structures adjacent to
adenoma
Detecting calcifications in association with
macro adenoma
NCCT+ CECT head/sella with thin coronal cuts:
findings as seen in X-Rays
iso dense to adjacent brain parenchyma
intense contrast enhancement
calcifications uncommon (< 5%)
apoplexy- hyper density
150. CT HEAD
NCCT+ CECT head/ sella with thin coronal cuts:
Neck hyper extended(Reduces dental artifacts)
1.5 -2.0 mm cuts from tuberculum to dorsum sella
MICROADENOMAS
Focal hypo intensity
Increased vertical height
Asymmetrical convexity of superior surface
MACROADENOMAS
Isodense or heterogenous with mixed iso and hypo
areas intense contrast enhancement
151.
152. MRI
Better visualization of optic apparatus/carotids
Multiplanar display
Coronal images
Examining asymmetries
Minimal volume artifacts
Sagittal images
Orientation of pituitary in relation to sphenoid sinus
Axial images
Useful in lesions with parasellar extension
Sensitivity for pituitary adenomas 90%
Sensitivity post contrast 95%
153. • Sagittal and coronal T1WI sellar and parasellar
region with/without contrast 2.5mm thin
contiguous slices and 5mm slices axial T2WI of
whole brain.
• Normal pituitary is iso intense to gray matter on
T1WI with contrast enhancing
• Pituitary adenoma classified based on size:
microadenoma <10mm
macroadenoma >10mm
giant pit adenoma >40mm
MRI
154.
155.
156. MRI
Routine 1-2 Tesla MRI produce 2-3 mm
slices
Newer techniques : reduce false negatives
and can reduce acquisition time
I. Volume imaging techniques (3 –D Fourier
transform)
II. Fast spin echo
157. MRI
T1W
More sensitive
Better anatomical details of extra-axial
structures
Obtained in shorter time period
Normal anterior lobe is intermediate grey
Posterior lobe is bright
Paramagnetic contrast agents further
improve delineation
158. MRI
Microadenoma
• Seen as area of focal hypo-intensity
• Usually well defined, laterally situated
• Focal convexity upward
• Displacement of stalk to opposite side
• Relative hypo-intensity on immediate post
contrast sequences
160. MRI
Dynamic Imaging
• Consists of a series of images at the same location to
detect temporal changes in the signal intensity
• Dynamic contrast study done by 5 T1WI turbo spin
3mm thin slices repetitively at 20,40,60,80,100 sec
after 10ml contrast injection at 2ml/sec.
• Sequential coronal images at 20- 30 sec intervals
following contrast injection
• Micro adenoma enhance and wash out quickly as
compared to normal gland post contrast and hence
appear hypointense, deviation of stalk, bulging of
inferior and superior margin
163. MRI
Macroadenoma
Soft tissue sellar mass of intermediate signal
intensity on T1W images
Hyperintense on T2W
Enhancing diffusely on contrast
Superior spread most common
(Grows through diaphragma sellae - figure of 8
image )
164.
165. Differential Diagnosis
Craniopharyngioma
Rathke’s cleft cyst
Meningiomas arising from tuberculum sella, planum
sphenoidale, anterior clinoid, posterior clinoid, medial
sphenoid wing
Aneurysms of cavernous/supraclinoid ICA, rarely
basilar top
Empty sella turcica
Chordomas
Dermoids/epidermoids
Metastasis especially in skull base
166.
167. CRANIOPHYRNGIOMAS
Suprasellar location
On CT - heterogenous density
masses with areas of cyst
formation and calcification
Solid tissue is contrast
enhancing
On MRI variable signal
intensity lesions
Cysts are using high signal
168. GERMINOMAS
Seen usually in children
(pineal region)
When suprasellar midline in
location, behind infundibulum
Hypo on T1W, hyper on T2W,
contrast enhancing
Rathke’ cleft cyst
Anterior half of sella turcica
In front of pituitary stalk
169. PITFALLS
False negatives
• Especially with Cushing's disease in conventional
spin echo MRI
• Pneumatized anterior clinoid process
False positives
• Small pars intermedia cysts
• Clinically silent infarcts
• Foci of necrosis
170. Role Of Pet In Pituitary Adenoma
Primarily for monitoring treatment
11C-methionine and 18–FDG for metabolic
mapping.
Highest metabolic rate with prolactinoma
followed by growth hormone tumors.
171. Management - Hormonal overproduction
Prolactinoma:
Dopaminergic agonists
(bromocriptine,
cabergoline and
Quinagolide)
Growth hormone-secreting tumors:
Gonadotropin-secreting pituitary tumor:
Thyrotropin-secreting tumors
• Surgery, often followed by radiation
therapy.
• Medical treatment (Octreotide)
Nonsecretory pituitary adenomas
• Surgery
• If surgery is contraindicated,
medical treatment (Bromocriptine or Octreotide)
172. Management - Hormonal overproduction
Corticotropin-secreting pituitary tumors:
• surgery and radiation therapy
# Medical therapy:
• Central acting agents:
(bromocriptine, valproic acid, and cyproheptadine).
• Peripheral acting agents:
(ketoconazole, mitotane, and metyrapone).